HEPTA Medical
HEPTA Medical is developing a unique minimally invasive non surgical treatment modality for early lung cancer. The company is working on a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and ablate pulmonary nodules, the precursor of lung cancer, without the need for surgery or radiation.
HEPTA Medical has finalized its prototype design and completed its pre-clinical validation. The company is currently looking for a strategic partner to get into the clinic.
Sector
Medical Devices
Strategies
MD Start
Status
Live
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.